Investing.com - Financial Markets Worldwide

Sinocelltech Group Ltd (688520)

Shanghai
Currency in CNY
66.52
+0.22(+0.33%)
Delayed Data·
688520 Scorecard
Full Analysis
Net income is expected to grow this year
688520 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Unlock Value
Day's Range
65.6066.88
52 wk Range
31.0789.04
Key Statistics
Edit
Bid/Ask
66.52 / 66.61
Prev. Close
66.3
Open
65.69
Day's Range
65.6-66.88
52 wk Range
31.07-89.04
Volume
1.9M
Average Volume (3m)
6.64M
1-Year Change
85.49%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
688520 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Technical Analysis
Sell
Analysts Sentiment
Strong Buy
Price Target
49.00
Downside
-26.34%
Members' Sentiments
Bearish
Bullish
ProTips
Unlock All 16
Impressive gross profit margins
Unlock InvestingPro

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Sinocelltech Group Ltd Company Profile

Sinocelltech Group Limited, a biotech company, engages in the research and development, and industrialization of recombinant proteins, monoclonal antibodies, and innovative vaccines in China. The company offers Anpingxi an antibody drug and anti-tumor product; Anjiayin for the treatment of the rare disease hemophilia A; coronavirus 2-valent, a trimer protein vaccine; and mutant strain recombinant protein vaccines SCTV01C and SCTV01E. Its pipeline products include SCT630 used for the treatment of autoimmune diseases; SCT510 for the treatment of solid tumors; SCT-I10A, a monoclonal antibody injection which is in phase 3 trials for the treatment of solid tumors; SCTV01, a new generation vaccine which is in phase 3 trials for the treatment of corona virus; SCT510 for the treatment of solid tumors; SCT200, a monoclonal antibody injection for the treatment of solid tumors; and SCT1000, which is in phase 3 clinical trials for the treatment of human papillomavirus, as well as SCTA01 which is in phase 2/3 clinical research trials for the treatment of SARS COV-2. The company was founded in 2007 and is based in Beijing, China. The company operates as a subsidiary of Lhasa Alike Investment Consulting Co., Ltd.

Industry
Biotechnology & Medical Research
Sector
Healthcare
Employees
2277
Market
China

Compare 688520 to Peers and Sector

Metrics to compare
688520
Peers
Sector
Relationship
P/E Ratio
290.8x−19.8x−0.5x
PEG Ratio
1.870.270.00
Price/Book
144.5x6.8x2.6x
Price / LTM Sales
12.2x21.9x3.3x
Upside (Analyst Target)
−26.1%11.1%43.3%
Fair Value Upside
Unlock−17.0%6.9%Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 49.00
(-26.34% Downside)

Earnings

Latest Release
Apr 25, 2025
EPS / Forecast
0.13 / --
Revenue / Forecast
519.74M / --
EPS Revisions
a
a
Unlock
Last 90 days

688520 Income Statement

FAQ

What Stock Exchange Does Sinocelltech Group Trade On?

Sinocelltech Group is listed and trades on the Shanghai Stock Exchange stock exchange.

What Is the Stock Symbol for Sinocelltech Group?

The stock symbol for Sinocelltech Group is "688520."

What Is the Sinocelltech Group Market Cap?

As of today, Sinocelltech Group market cap is 29.53B.

What Is Sinocelltech Group's Earnings Per Share (TTM)?

The Sinocelltech Group EPS (TTM) is 0.21.

When Is the Next Sinocelltech Group Earnings Date?

Sinocelltech Group will release its next earnings report on 29 Aug 2025.

From a Technical Analysis Perspective, Is 688520 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has Sinocelltech Group Stock Split?

Sinocelltech Group has split 0 times.

How Many Employees Does Sinocelltech Group Have?

Sinocelltech Group has 2277 employees.

What is the current trading status of Sinocelltech Group (688520)?

As of 11 Aug 2025, Sinocelltech Group (688520) is trading at a price of 66.52, with a previous close of 66.30. The stock has fluctuated within a day range of 65.60 to 66.88, while its 52-week range spans from 31.07 to 89.04.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.